{{short description|American clinician-scientist and drug developer}} {{Infobox scientist | name = Hal V. Barron |image = |image_size = |birth_date = |birth_place = |death_date = |death_place = |residence = |citizenship = |nationality = |ethnicity = |field = Physician |work_institutions = University of California, San Francisco (UCSF), Calico (company), Genentech, Hoffmann-La Roche |alma_mater = Washington University in St. Louis, <br /> Yale University, University of California, San Francisco |doctoral_advisor = |notable_students = |known_for = |author_abbrev_bot = |author_abbrev_zoo = |influences = |influenced = |prizes = |religion = |footnotes = |signature = }}
'''Hal V. Barron''' (born 1962) is an American clinician-scientist and drug developer who served as president of research and development at GlaxoSmithKline from March 2018<ref>{{cite web|url=https://www.cnbc.com/wires/|title=Wires|website=Cnbc.com|accessdate=13 February 2019}}</ref> until 2022, when he resigned in order to join the cellular reprogramming venture Altos Labs in August of that year.<ref name="Carroll2022">{{cite news |last1=Carroll |first1=John |title=What kind of biotech startup wins a $3B syndicate, woos a gallery of marquee scientists and recruits GSK's Hal Barron as CEO in a stunner? Let Rick Klausner explain |url=https://endpts.com/what-kind-of-biotech-startup-wins-a-3b-syndicate-woos-a-gallery-of-marquee-scientists-and-recruits-gsks-hal-barron-as-ceo-in-a-stunner-let-rick-klausner-explain/ |access-date=19 June 2022 |work=Endpoints News |date=January 19, 2022}}</ref><ref name="AltosExec">{{cite web |title=Altos Labs: Executive Leadership |url=https://altoslabs.com/team/executive-leadership/rick-klausner/ |publisher=Altos Labs |access-date=19 June 2022}}</ref><ref name=Kollewe2022>{{cite news|last1=Kollewe|first1=Julia|url= https://www.theguardian.com/business/2022/jan/19/gsks-top-scientist-jumps-ship-in-new-blow-for-pharmaceutical-firm |title=GSK's top scientist jumps ship in new blow for pharmaceutical firm|website=The Guardian |date=19 January 2022 |accessdate=June 19, 2022}}</ref> Prior to this he served as president of research and development at Calico.<ref>{{cite web|url=https://plus.google.com/108880830087528406119/posts/2MdyrE2DX3z|title=I'm excited to announce Calico, a new company that will focus on health and w...|website=Plus.google.com|accessdate=13 February 2019}}</ref> He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche.<ref>{{Cite web |url=http://www.roche.com/media/media_releases/med-cor-2009-04-14.htm |title=Roche - Roche and Genentech announce organizational and leadership decisions |access-date=2014-06-04 |archive-url=https://web.archive.org/web/20090419192759/http://www.roche.com/media/media_releases/med-cor-2009-04-14.htm |archive-date=2009-04-19 |url-status=dead }}</ref>
==Career== Barron joined Genentech in 1996 as a clinical scientist and was promoted in 2002 to Vice President of Medical Affairs.<ref>{{cite web|url=https://www.gene.com/media/press-releases/5067/2002-05-14/genentech-appoints-hal-barron-vice-presi|title=Genentech: Press Releases - Tuesday, May 14, 2002|website=Gene.com|accessdate=13 February 2019}}{{Dead link|date=July 2025 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> In 2002 Barron was promoted to vice president of medical affairs and in 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed executive vice president.
On September 18, 2013, Barron was named President of Research and Development of Calico, a new company focusing on the biology of aging.<ref>{{cite web |url=http://www.calicolabs.com/ |title=Home |website=calicolabs.com}}</ref> The company was created and funded by Google.<ref>{{cite web|url=http://googlepress.blogspot.com/2013/09/calico-announcement.html|title=Google announces Calico, a new company focused on health and well-being – News announcements – News from Google – Google|website=Googlepress.blogspot.com|accessdate=13 February 2019}}</ref>
On November 8, 2017, Barron became the new CSO and research chief at GlaxoSmithKline amid a shake-up from its new CEO Emma Walmsley. Barron was quoted: "GSK is a company with a rich history of innovation, with many talented scientists who care deeply about translating great science into therapies that make a meaningful difference for patients. I believe there is a significant opportunity to accelerate this effort and am looking forward to joining Emma and the team on this mission.”<ref>{{cite web|url=https://www.fiercebiotech.com/biotech/roche-calico-vet-hal-barron-takes-gsk-r-d-hot-seat-as-vallance-out|title=Roche, Calico vet Hal Barron takes GSK R&D hot seat, as Vallance out - FierceBiotech|website=Fiercebiotech.com|date=8 November 2017|accessdate=13 February 2019}}</ref>
In April 2019, it was publicly reported that Barron spent excessively on travel expenses during the previous year. The total expenses exceeded $807,000 (£620,000). Shareholders, investors, and rank-and-file employees have all expressed concern tilting towards outrage that he has been allow to spend so freely while others are constrained and employee layoffs continue.<ref>{{Cite news |last=Mkandawire |first=Vinjeru |date=2019-04-14 |title=GSK's jet-set scientist racks up travel bill worth nearly $800k |language=en-GB |work=The Telegraph |url=https://www.telegraph.co.uk/business/2019/04/14/gsks-jet-set-scientist-racks-travel-bill-worth-nearly-800k/ |access-date=2022-10-19 |issn=0307-1235}}</ref>
In January 2022, it was announced that Barron will join Altos starting on 1 August 2022 at newly created biotech company Altos Labs, based in San Francisco.<ref name=Kollewe2022/>
Barron's current academic positions at the University of California, San Francisco include Associate Adjunct Professor of Epidemiology and Biostatistics, and Associate Clinical Professor of Medicine/Cardiology. He has been issued several patents for his work in thrombosis and angiogenesis, and has published more than 80 papers in peer-reviewed scientific journals.<ref>{{cite web|url=https://pubmed.ncbi.nlm.nih.gov/?term=barron+hv+%5Bau%5D|title=Pubmed search|accessdate=15 April 2019}}</ref> He was a member of the board of directors at Alexza Pharmaceuticals, and is a current member of the board of directors at Juno Therapeutics.<ref>{{cite web|url=https://www.junotherapeutics.com/about-us/our-people/hal-barron/|title=Hal Barron – Juno Therapeutics|website=Junotherapeutics.com|accessdate=13 February 2019}}</ref>
==Education== Barron received his medical degree from Yale School of Medicine and holds a Bachelor of Science degree in engineering physics from Washington University in St. Louis. He completed his training in medicine and cardiology at the University of California, San Francisco.
==References== {{Reflist}}
{{DEFAULTSORT:Barron, Hal V}} Category:1962 births Category:American biotechnologists Category:Living people Category:Genentech people Category:GSK plc people Category:Hoffmann-La Roche people Category:Yale School of Medicine alumni Category:Washington University in St. Louis alumni Category:Washington University in St. Louis physicists Category:University of California, San Francisco faculty Category:University of California, San Francisco alumni Category:American epidemiologists Category:American biostatisticians Category:American cardiologists Category:American corporate directors Category:American transhumanists